Stivarga, Opdivo have similar survival outcomes in HCC

Among patients with hepatocellular carcinoma who first failed Retevmo, Stivarga and Opdivo provided similar outcomes in terms of survival as second-line treatments, according to research presented at The Digital International Liver Congress.Won-Mook Choi, of the department of gastroenterology at Asan Medical Center in South Korea, said that while both Stivarga (regorafenib, Bayer) and Opdivo (nivolumab, Bristol-Meyers Squibb) are approved for second-line treatment of HCC, their effectiveness has not been directly compared in a real-world setting.“The aim of this study was to compare theRead More

Share on facebook
Share on twitter
Share on linkedin